Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Income from Continuing Operations (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Income from Continuing Operations for 7 consecutive years, with 236624000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 130.95% year-over-year to 236624000.0, compared with a TTM value of 682688000.0 through Dec 2025, down 111.98%, and an annual FY2025 reading of 682688000.0, down 111.98% over the prior year.
  • Income from Continuing Operations was 236624000.0 for Q4 2025 at Avidity Biosciences, down from 174062000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 23841000.0 in Q1 2021 and bottomed at 236624000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 75412700.0, with a median of 52212500.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations crashed 291.8% in 2021, then dropped 2.57% in 2023.
  • Year by year, Income from Continuing Operations stood at 38492000.0 in 2021, then tumbled by 31.07% to 50453000.0 in 2022, then fell by 19.59% to 60338000.0 in 2023, then tumbled by 69.81% to 102458000.0 in 2024, then tumbled by 130.95% to 236624000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for RNA at 236624000.0 in Q4 2025, 174062000.0 in Q3 2025, and 156664000.0 in Q2 2025.